Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 HIV preventive vaccine study of Ad26.Mos4.HIV plus adjuvanted gp140
2018-003666-13Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2019
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Ad26.Mos4.HIV, Clade C gp140 HIV bivalent vaccine and clade c gp140 + mosaic gp140 in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Confirmed HIV-1 infection. Started Jul 2019; status: recruiting.
02
Drugs
Ad26.Mos4.HIVClade C gp140 HIV bivalent vaccineclade c gp140 + mosaic gp140
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2018-003666-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003666-13.